Clinical Trial of Licartin Combined with Radiofrequency Ablation for Prevention of Hepatocellular Carcinoma Recurrence

Clinical Assessment of Antibody-Targeted Therapy of HBV-Related HCC and New Method Research and Application

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-10000837

Enrollment

Unknown

Registered

2010-04-14

Start date

2010-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Group A:Licartin combined with conventional RFA

Group B:Conventional RFA

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients are entirely voluntary, good compliance; sign the informed consent form; 2. Age 18 to 75 years; 3. To be diagnosed as hepatocellular carcinoma by pathology or clinical diagnosis; 4. Liver function is Child-Pugh class A or B; 5. Expected survival >=3 months; 6. Barcelona Clinic Liver Cancer (BCLC) classification stage 0, A , or B; 7. Number of tumor lesions =3*10^9/L; platelet counts >=50*10^9/L.

Exclusion criteria

Exclusion criteria: 1. Allergic to biological agents and hypersensitiveness; 2. Pregnant or breast-feeding women; 3. Patients in whom the initial skin test are positive for Metuximab antibody; 4. Patients with hypothyroidism.

Design outcomes

Primary

Measure	Time frame
Overall tumor recurrence;Time to tumor recurrence;Overall surviva;	—

Secondary

Measure	Time frame
Safet;	—

Countries

China

Contacts

Public ContactZhi-Nan Chen

znchen@fmmu.edu.cn+86 029 84773243

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026